ESALY

Eisai Co., Ltd. [ESALY] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

ESALY Stock Summary

In the News

03:58 29 Mar 2024 ESALY

Alzheimer's Disease Drug Development: Another Lost Year

Investing in most current Alzheimer's drug companies is not recommended because they are not likely to modify the disease. Compounds that inhibit oxidative stress may only slow down the progression of Alzheimer's disease over the short term. Anavex's blarcamesine, Cyclo Therapeutics Trappsol Cyclo, Green Valley's GV-971, aromatherapy, and panax ginseng not only inhibit the formation of oxidants but scavenge them and reverse part of their damage.

12:17 29 Mar 2024 ESALY

Biogen Hits Buy Zone On A Fresh Win In Alzheimer's Disease; Eli Lilly, Eisai Shares Jump

Biogen stock jumped into a buy zone Thursday after Medicare officials said they would pay for some Alzheimer's treatments.

12:08 29 Mar 2024 ESALY

3 Stocks to Buy That Could Be the Next Biotech Breakthrough

In general, biotech stocks are not ideal for conservative investors. The companies in search of the next medical breakthrough are inherently risky.

07:02 29 Mar 2024 ESALY

Merck and Eisai report disappointing results from trials of combination treatment for melanoma and colorectal cancer

Merck MRK and its Japanese partner Eisai said Friday they are discontinuing the Phase 3 LEAP-003 trial evaluating Keytruda plus Lenvima for the first-line treatment of adults with unresectable or metastatic melanoma after data showed the combination did not produce an improvement in overall survival, or OS, compared with Keytruda alone. OS was one of two primary endpoints; the other, progression-free survival, did show a statistically significant improvement in an earlier interim analysis of data.

12:33 29 Mar 2024 ESALY

The Cream Of The Crop: 5 Biotech Stocks That Outrank 91% Of All Stocks

The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.

08:08 29 Mar 2024 ESALY

Eisai to Present Research from Oncology Portfolio at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women's Cancer

Study Findings in Patients with Recurrent or Advanced Endometrial Carcinoma Who Were Rechallenged With Platinum Chemotherapy Will Be Featured in an Oral Plenary Session Additional Subgroup Analyses from the Pivotal Phase 3 Study 309/KEYNOTE-775 Trial May Provide Further Information About Treating Patients with Advanced Endometrial Carcinoma NUTLEY, N.J. , March 23, 2023 /PRNewswire/ -- Eisai will present two abstracts at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women's Cancer (#SGOMtg), which is taking place in-person in Tampa, Florida and virtually from March 25-28.

09:27 29 Mar 2024 ESALY

FDA will review Eisai's and Biogen's Alzheimer's treatment Leqembi with decision on full approval expected in early July

Medicare has agreed to provide broader coverage once Leqembi receives full FDA approval.

08:31 29 Mar 2024 ESALY

Maker of promising Alzheimer's drug Leqembi expects full FDA approval this summer, expanded Medicare coverage

Even if the FDA grants full approval of the Alzheimer's treatment Leqembi, the rollout of the treatment will take years.

05:19 29 Mar 2024 ESALY

Alzheimer's drug Leqembi: Eisai U.S. president

Eisai U.S. President Ivan Cheung joins Yahoo Finance Live to discuss the latest news surrounding Alzheimer's treatment with Leqembi.

10:59 29 Mar 2024 ESALY

Eisai Co., Ltd. (ESALF) Q3 2022 Earnings Call Transcript

Eisai Co., Ltd. (OTCPK:ESALF) Q3 2022 Earnings Conference Call February 6, 2023 3:15 AM ET Company Participants Tatsuyuki Yasuno - Senior Vice President, Chief Financial Officer, Chief IR Officer Ivan Cheung - Senior Vice President, Global Alzheimer's Disease Officer, President, Americas Region Chairman & Chief Executive Officer, Eisai Inc. Akiko Nakahama - Vice President, Chief Portfolio Officer, AD Filing and Registration Japan/Asia Lead Quality Conference Call Participants Hidemaru Yamaguchi - Citigroup Global Markets Japan Inc. Motoya Kohtani - Nomura Securities Co., Ltd.

ESALY Financial details

Company Rating
Strong Buy
Market Cap
17.64B
Income
27.06B
Revenue
737.1B
Book val./share
2698.91
Cash/share
937.9
Dividend
-
Dividend %
-
Employees
11.09K
Optionable
No
Shortable
Yes
Earnings
06 Nov 2022
P/E
94.43
Forward P/E
-
PEG
-26.38
P/S
3.47
P/B
3.3
P/C
-
P/FCF
-148.94
Quick Ratio
0.86
Current Ratio
1.95
Debt / Equity
0.19
LT Debt / Equity
0.11
-
-
EPS (TTM)
94.34
EPS next Y
-
EPS next Q
-
EPS this Y
8.51%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-2.5%
Revenue last 5Y
4.74%
Revenue Q/Q
7.57%
EPS Q/Q
138.1%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
0%
Inst Trans
0%
ROA
2%
ROE
3%
ROC
-
Gross Margin
74%
Oper. Margin
-
Profit Margin
4%
Payout
170%
Shs Outstand
286.7M
Shs Float
0
-
-
-
-
Target Price
-
52W Range
36.88-73.9035
52W High
-
52W Low
-
RSI
-
Rel Volume
10.97
Avg Volume
30.26K
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
-
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-

ESALY Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-03-31

Metric History 2018-03-312019-03-312020-03-312021-03-31 2022-03-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
2.09K2.24K2.43K2.25K2.64K
Net income per share
180.97221.12424.77146.94159.44
Operating cash flow per share
522.37361.8358.55257.64410.11
Free cash flow per share
436.04265.44183.34124.57268.98
Cash per share
1.01K1.03K892.33868.691.08K
Book value per share
2.07K2.19K2.37K2.45K2.61K
Tangible book value per share
1.12K1.25K1.49K1.56K1.69K
Share holders equity per share
2.07K2.19K2.37K2.45K2.61K
Interest debt per share
614.72489.97318.84318.35336.85
Market cap
1726.53B1806.56B1738.67B1794.24B1633.48B
Enterprise value
1629.15B1659.02B1574.37B1635.4B1418.74B
P/E ratio
33.328.514.2842.635.73
Price to sales ratio
2.882.812.52.782.16
POCF ratio
11.5417.4216.9224.2913.89
PFCF ratio
13.8223.7433.0850.2521.18
P/B Ratio
2.912.882.562.552.18
PTB ratio
2.912.882.562.552.18
EV to sales
2.722.582.262.531.88
Enterprise value over EBITDA
15.7614.469.6918.214.66
EV to operating cash flow
10.891615.3222.1412.07
EV to free cash flow
13.0421.829.9645.818.4
Earnings yield
0.030.040.070.020.03
Free cash flow yield
0.070.040.030.020.05
Debt to equity
0.290.220.130.130.13
Debt to assets
0.170.130.080.080.08
Net debt to EBITDA
-0.94-1.29-1.01-1.77-2.22
Current ratio
2.221.92.072.022.04
Interest coverage
26.0455.385.8438.0634.51
Income quality
2.891.640.841.752.45
Dividend Yield
0.020.020.030.030.03
Payout ratio
0.830.680.381.091
Sales general and administrative to revenue
0.310.360.370.440.48
Research and developement to revenue
0.230.230.20.230.23
Intangibles to total assets
0.260.260.260.260.23
Capex to operating cash flow
-0.17-0.27-0.49-0.52-0.34
Capex to revenue
-0.04-0.04-0.07-0.06-0.05
Capex to depreciation
-0.94-1.03-1.49-1.05-1.05
Stock based compensation to revenue
00000
Graham number
2.9K3.3K4.75K2.85K3.06K
ROIC
0.070.080.160.050.06
Return on tangible assets
0.070.080.150.050.05
Graham Net
-367.49-319.59-247.13-245.95-377.41
Working capital
294.24B265.94B269.44B262.33B327.27B
Tangible asset value
321.18B357.82B427.85B447.52B484.32B
Net current asset value
100.97B142.14B161.9B156.28B172.82B
Invested capital
0.290.220.130.130.13
Average receivables
00000
Average payables
69.42B72.81B77.2B85.71B101.31B
Average inventory
81.9B74.41B66.81B75.43B92.06B
Days sales outstanding
00000
Days payables outstanding
123.5153.38159.72213.94225.61
Days of inventory on hand
146.78134.31136.56192.6206.7
Receivables turnover
00000
Payables turnover
2.962.382.291.711.62
Inventory turnover
2.492.722.671.91.77
ROE
0.090.10.180.060.06
Capex per share
-86.33-96.36-175.21-133.07-141.13

Quarterly Fundamentals Overview

Last date of statement is 2022-12-31 for Q3

Metric History 2021-12-312022-03-312022-06-302022-09-30 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
707.98665.79642.66607.93654.03
Net income per share
45.51-48.3897.5513.3631.81
Operating cash flow per share
16.62154.8913.76-79.46-24.12
Free cash flow per share
-20.31127.21-41.66-96.31-49.02
Cash per share
904.61.08K1.01K925.77937.9
Book value per share
2.56K2.61K2.81K2.89K2.7K
Tangible book value per share
1.66K1.69K1.82K1.77K1.75K
Share holders equity per share
2.56K2.61K2.81K2.89K2.7K
Interest debt per share
315.07332.73332.41332.47525.6
Market cap
1867.09B1633.48B1628.45B2227.02B2527.71B
Enterprise value
1698.59B1418.74B1435.53B2057.4B2409.83B
P/E ratio
35.78-29.4414.56145.2569.27
Price to sales ratio
9.28.568.8412.7713.48
POCF ratio
391.9236.78412.79-97.71-365.43
PFCF ratio
-320.6444.78-136.34-80.62-179.79
P/B Ratio
2.542.182.022.693.27
PTB ratio
2.542.182.022.693.27
EV to sales
8.377.437.7911.812.85
Enterprise value over EBITDA
67.1-147.8276.12242.45122.02
EV to operating cash flow
356.5531.95363.89-90.27-348.39
EV to free cash flow
-291.738.9-120.19-74.48-171.41
Earnings yield
0.01-0.010.0200
Free cash flow yield
00.02-0.01-0.01-0.01
Debt to equity
0.120.130.120.110.19
Debt to assets
0.080.080.070.080.12
Net debt to EBITDA
-6.6622.37-10.23-19.99-5.97
Current ratio
1.922.042.062.21.95
Interest coverage
38.08-36.9422.25-3.1315.53
Income quality
0.34-3.580.4114.35-0.73
Dividend Yield
0.0100.0100.01
Payout ratio
1.7600.8202.52
Sales general and administrative to revenue
0.50.580.50.510.49
Research and developement to revenue
0.210.250.210.250.21
Intangibles to total assets
0.240.230.240.260.24
Capex to operating cash flow
-2.22-0.18-4.030.211.03
Capex to revenue
-0.05-0.04-0.09-0.03-0.04
Capex to depreciation
-1.07-0.86-1.62-0.49-0.7
Stock based compensation to revenue
00000
Graham number
1.62K1.69K2.48K931.761.39K
ROIC
0.02-0.010.0300.01
Return on tangible assets
0.01-0.010.0300.01
Graham Net
-359.59-377.41-356.84-306.27-434.39
Working capital
282.06B327.27B319.05B318.84B296.44B
Tangible asset value
474.8B484.32B520.66B508.15B500.47B
Net current asset value
178.37B172.82B176.43B174.81B156.12B
Invested capital
0.120.130.120.110.19
Average receivables
00000
Average payables
83.46B99.35B102.09B86.47B72.85B
Average inventory
91.28B95.76B101.26B108.96B117.64B
Days sales outstanding
00000
Days payables outstanding
184.47191.69182.46153.2132.63
Days of inventory on hand
188.28175.62196.52228.15232.75
Receivables turnover
00000
Payables turnover
0.490.470.490.590.68
Inventory turnover
0.480.510.460.390.39
ROE
0.02-0.020.0300.01
Capex per share
-36.93-27.67-55.42-16.84-24.9

ESALY Frequently Asked Questions

What is Eisai Co., Ltd. stock symbol ?

Eisai Co., Ltd. is a JP stock and trading under the symbol ESALY

What is Eisai Co., Ltd. stock quote today ?

Eisai Co., Ltd. stock price is $- today.

Is Eisai Co., Ltd. stock public?

Yes, Eisai Co., Ltd. is a publicly traded company.

Something similar

Top by Market Cap
Check Those
Similar Market Cap